Diabetes is a chronic disease that affects a large part of the United States population. The majority of patients with diabetes will experience gastrointestinal symptoms. One of the most troublesome gastrointestinal symptoms that diabetes can cause is diarrhea, otherwise known as "Diabetic Diarrhea." This occurs because diabetes does damage to nerves that control the gut and prevent it from functioning normally. Currently, there are only several medications used to treat the symptoms of Diabetic Diarrhea, but many of these medications have serious side effects or do not work well.
We are investigating the drug eluxadoline for the treatment of Diabetic Diarrhea. Eluxadoline is a gut-specific medication that is FDA approved to treat diarrhea related to irritable bowel syndrome (IBS-D). Our hypothesis is eluxadoline will safely and successfully reduce diarrhea symptoms (number of stools and less liquid stools) and improve the quality of life in patients with Diabetic Diarrhea when compared with placebo. Each patient with Diabetic Diarrhea who participates will take both eluxadoline and a placebo drug at separate times over a period of several months as part of a crossover study design. While on each medication, eluxadoline or placebo, the participants will keep a diary of symptoms and will be followed by the medical team through a combination of office visits and questionnaires. There will be five planned office visits and intermittent phone calls (questionnaires, surveys) over the 140-day study period. Participants will not be permitted to use any other anti-diarrhea medication during the study period and will continue on medication for management of their diabetes.

开始日期2022-07-01

申办/合作机构

Temple University Graduate School

[+1]

NCT04880876 / Enrolling by invitation临床3期

A Phase 3, Long-term Safety Study of Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.

开始日期2021-08-13

申办/合作机构

Allergan Plc

NCT03489265 / Withdrawn临床2期IIT

Treatment of Diarrhea-Associated Fecal Incontinence With Eluxadoline

Accidental bowel leakage (fecal incontinence) increases in people who have diarrhea and sensations of urgency to have a bowel movement. Drugs such as loperamide (Imodium) that reduce diarrhea improve accidental bowel leakage, but loperamide has disadvantages: it is difficult to find a dose that does not cause constipation, and it does not reduce urge sensations. Eluxadoline is a new drug that is effective for reducing diarrhea, abdominal pain, and urgency in patients with irritable bowel syndrome, and it may be less likely than loperamide to cause severe constipation. Therefore, eluxadoline may help patients manage accidental bowel leakage caused by diarrhea. The chemical name for Viberzi® is eluxadoline.
The primary aims of this study are to find out if eluxadoline at a dose of 100 mg orally twice a day will reduce the average number of days the patient has accidental bowel leakage, and to see if the rate of accidental bowel leakage increases when the patient stops taking eluxadoline. Additional goals are to find out if eluxadoline decreases diarrhea and urge sensations.
This is a small (pilot) study to show whether eluxadoline is an effective way of treating accidental bowel leakage. If the study shows this, a larger study will be needed. There are three phases to this 12-week study: (1) A two-week run-in period to see if the patient meets the inclusion criteria. (2) Two months for treatment including one month on eluxadoline and one on placebo (sugar pills) twice a day. (3) A two-week follow-up to see what happens when you stop taking eluxadoline.
To participate in the study, patients should be aged 18 or older. Patients with inflammatory bowel disease, anal fissures, or congenital malformations will be excluded.
The primary outcome is the average number of days per week with any solid or liquid bowel accidents. Additional information includes: (1) Number of days per week the patient takes loperamide, (2) days per week with loose or watery stools, (3) days per week with moderate to strong urge sensations, and (4) questionnaires to measure the severity of accidental bowel leakage, quality of life, anxiety, and depression. There will be up to 38 patients in the study.

开始日期2019-04-01

申办/合作机构

The University of North Carolina at Chapel Hill

[+1]

100 项与艾沙度林相关的临床结果

登录后查看更多信息

100 项与艾沙度林相关的转化医学

登录后查看更多信息

100 项与艾沙度林相关的专利（医药）

登录后查看更多信息

149

项与艾沙度林相关的文献（医药）

2024-03-03·Expert Opinion on Investigational Drugs

Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs

Review

作者: Nikfar, Shekoufeh ; Mozaffari, Shilan ; Abdollahi, Mohammad

INTRODUCTIONIrritable bowel syndrome (IBS) has a significant impact on society and quality of life. Current treatments are ineffective, and new investigational drugs are necessary.AREAS COVEREDNumerous potential therapies are developing, targeting different areas such as cannabinoid signaling, opioid receptors, tachykinin (NK2) receptors, β3-adrenergic receptors, intestinal microbiota, inflammation, and 5HT receptors. Clinical trial evidence has shown that loperamide, eluxadoline, alosetron, ramosetron, bile acid sequestrants, and rifaximin can modulate GI alterations and benefit patients with IBS-D. Among the potential therapies, ibodutant, ibudilast, blautix, BOS-589, solabegron, vibegron, olorinab, ebastine, and ORP-101 have demonstrated possible effects but remain confirmed.EXPERT OPINIONIndividuals with IBS-D require cost-effective treatment options that do not impede their productivity or that of their caregivers. This is necessary for consistent healthcare and improved quality of life. Therefore, we should focus on developing new, efficient, and affordable medications for IBS-D. The government, insurers, and society must recognize this need and collaborate to ensure its fulfillment.

2023-10-01·Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology

COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, Spain.

Article

作者: González-Pérez, Juan-Manuel ; Rosón, Benigno ; Salas, Antonio ; Nartallo-Penas, Victoria ; Rodríguez-Tenreiro-Sánchez, Carmen ; Otero-Barrós, María-Teresa ; Mirás-Carballal, Susana ; Gómez-Carballa, Alberto ; Durán-Parrondo, Carmen ; Pardo-Seco, Jacobo ; Mallah, Narmeen ; López-Pérez, Luis-Ricardo ; Ares-Gómez, Sonia ; Martinón-Torres, Federico ; Rivero-Calle, Irene

BACKGROUNDStudies on vaccine effectiveness (VE) against COVID-19 in the pediatric population are outgoing. We aimed to quantify VE against SARS-CoV-2 in two pediatric age groups, 5-11 and 12-17-year-old, while considering vaccine type, SARS-CoV-2 variant, and duration of protection.METHODSA population-based test-negative control study was undertaken in Galicia, Spain. Children 5-11-year-old received the Comirnaty® (Pfizer, US) vaccine, while those aged 12-17-year-old received the Comirnaty® (Pfizer, US) or SpikeVax® (ModernaTX, Inc) vaccine. Participants were categorized into unvaccinated (0 doses or one dose with <14 days since vaccination), partially vaccinated (only one dose with ≥14 days, or two doses with <14 days after the second dose administration), and fully vaccinated (two doses with ≥14 days after the second injection). Adjusted odds ratios (OR) and their 95% confidence intervals (CI) were estimated using multiple logistic regression models. VE was calculated as (1-OR) * 100. Stratified and sensitivity analyses were performed.RESULTSIn the fully vaccinated 5-11-year-old children, VE against the Omicron variant was 44.1% (95% CI: 38.2%-49.4%). In the fully vaccinated 12-17-year-old individuals, VE was 83.4% (95% CI: 81.2%-85.3%) against Delta and 74.8% (95% CI: 58.5%-84.9%) against Omicron. Comirnaty® and SpikeVax® vaccines showed a similar magnitude of VE against Delta [Comirnaty® VE: 81.9% (95% CI: 79.3%-84.1%) and SpikeVax® VE: 85.3% (95% CI: 81.9%-88.1%)]. Comirnaty® (Pfizer, US; VE: 79.7%; 95% CI: 50.7%-92.4%) showed a slightly higher magnitude of protection against Omicron than SpikeVax® (ModernaTX, Inc), yet with an overlapping CI (VE: 74.3%; 95% CI: 56.6%-84.9%). VE was maintained in all age subgroups in both pediatric populations, but it declined over time.CONCLUSIONSIn Galicia, mRNA VE was moderate against SARS-CoV-2 infections in the 5-11-year-old populations, but high in older children. VE declined over time, suggesting a potential need for booster dose schedules.

2023-07-01·Computers in biology and medicine

Identification of core therapeutic targets for Monkeypox virus and repurposing potential of drugs against them: An in silico approach.

Article

作者: Sahu, Anshuman ; Mahanandia, Nimai Charan ; Gaur, Mahendra ; Subudhi, Bharat Bhusan ; Subudhi, Enketeswara ; Swain, Ranjit Prasad

Monkeypox virus (mpox virus) outbreak has rapidly spread to 82 non-endemic countries. Although it primarily causes skin lesions, secondary complications and high mortality (1-10%) in vulnerable populations have made it an emerging threat. Since there is no specific vaccine/antiviral, it is desirable to repurpose existing drugs against mpox virus. With little knowledge about the lifecycle of mpox virus, identifying potential inhibitors is a challenge. Nevertheless, the available genomes of mpox virus in public databases represent a goldmine of untapped possibilities to identify druggable targets for the structure-based identification of inhibitors. Leveraging this resource, we combined genomics and subtractive proteomics to identify highly druggable core proteins of mpox virus. This was followed by virtual screening to identify inhibitors with affinities for multiple targets. 125 publicly available genomes of mpox virus were mined to identify 69 highly conserved proteins. These proteins were then curated manually. These curated proteins were funnelled through a subtractive proteomics pipeline to identify 4 highly druggable, non-host homologous targets namely; A20R, I7L, Top1B and VETFS. High-throughput virtual screening of 5893 highly curated approved/investigational drugs led to the identification of common as well as unique potential inhibitors with high binding affinities. The common inhibitors, i.e., batefenterol, burixafor and eluxadoline were further validated by molecular dynamics simulation to identify their best potential binding modes. The affinity of these inhibitors suggests their repurposing potential. This work can encourage further experimental validation for possible therapeutic management of mpox.

项与艾沙度林相关的新闻（医药）

2023-06-07

·drugs

What Is Irritable Bowel Syndrome?

WEDNESDAY, June 7, 2023 -- People who suffer from irritable bowel syndrome (IBS) know it is a highly unpleasant chronic condition that can trigger abdominal pain, diarrhea and constipation. Here, experts will unravel the mysteries of IBS, exploring its causes, symptoms and treatments. And of course, don't forget about the role of diet. Experts will break down the best foods to eat and those to avoid for a happy gut. What is irritable bowel syndrome? According to the Mayo Clinic , irritable bowel syndrome is a common disorder targeting the gastrointestinal tract, encompassing the stomach and intestines. This chronic condition manifests through a range of distressing symptoms, including cramping, abdominal pain, bloating, excessive gas and the frustrating duo of diarrhea and constipation, which may occur individually or even simultaneously. Dealing with IBS requires a long-term management approach to address its persistent impact on daily life effectively. What causes IBS? The exact causes of irritable bowel syndrome remain uncertain, according to the National Institute of Diabetes and Digestive and Kidney Issues (NIDDK). However, experts believe that a combination of factors contributes to its development. IBS is considered a functional gastrointestinal (GI) disorder involving the intricate interaction between the brain and the gut. Here are some potential causes and factors that may play a role in IBS: Problems with brain-gut interaction. Brain and gut communication can impact the body's functioning, triggering IBS symptoms. This can include abnormal food movement through the digestive tract, resulting in changes in bowel movements, and experiencing pain even with average amounts of gas or stool in the gut. Stressful or difficult early-life events. Traumatic experiences during childhood, such as physical or sexual abuse, have been associated with an increased risk of developing IBS. Mental disorders. Conditions like depression, anxiety and somatic symptom disorder are more common among individuals with IBS and may contribute to its onset. Bacterial infections. Infections of the digestive tract caused by certain bacteria have been linked to developing IBS. Small intestinal bacterial overgrowth. In terms of increased numbers or changes in the bacterial type, an overgrowth of bacteria in the small intestine has been associated with IBS. Food intolerances or sensitivities. Some individuals with IBS may experience digestive symptoms triggered by specific foods, indicating intolerances or sensitivities to certain dietary components. The causes of IBS can vary among individuals, highlighting this condition's complexity. IBS symptoms In a recent video with Dr. Jennifer Webster , a pediatric gastroenterologist with Children’s Hospital of Philadelphia, she indicates that “the tricky thing about IBS is that there is no specific test that we can use to say 100% you have this . We do lots of testing to rule out other diseases. Similar to migraines, there isn’t a test, but we know that the pain is real and the symptoms are real.” While some studies suggest potential differences in the prevalence and severity of IBS symptoms between men and women, it is worth noting that the core symptoms are relatively similar. Here are some typical symptoms of IBS in men and women, according to Johns Hopkins Medicine : Abdominal pain or cramping. This is one of the hallmark symptoms of IBS. The pain is often described as a lower abdominal discomfort or cramping sensation that may vary in intensity. Bloating and distention. Many individuals with IBS experience bloating, a feeling of increased pressure or fullness in the abdomen. This can be accompanied by visible abdominal distention or swelling. Altered bowel habits. IBS can lead to changes in bowel movements. These changes can include diarrhea, characterized by loose or watery stools, and constipation, characterized by infrequent or difficult bowel movements. Some individuals may alternate between episodes of diarrhea and constipation. Excessive gas. Many people with IBS may notice increased gas production, leading to bloating, belching or flatulence. Urgency or an incomplete bowel movement. Some individuals with IBS may experience a sense of urgency to have a bowel movement or feel as though they haven't fully emptied their bowels after a bowel movement. Mucus in the stool. In some cases, people with IBS may notice the presence of mucus in their stool. Can a specific diet for IBS help with symptoms? When managing symptoms of IBS, changing your diet can play a significant role. Here are some common dietary recommendations for individuals with IBS: The NIDDK suggests the following foods to eat with irritable bowel syndrome : Increase fiber intake. Focus on incorporating sources of soluble fiber, such as oats, bananas, carrots and psyllium husk, into your diet. Avoid gluten. Avoiding gluten-containing grains like wheat, barley and rye may be beneficial for individuals with gluten sensitivity or celiac disease. Opt for gluten-free alternatives like quinoa, rice and gluten-free oats. Follow a low-FODMAP diet. Following a special diet known as the low- FODMAP diet may provide relief for some individuals with IBS. This diet for IBS involves temporarily restricting certain high-FODMAP foods, such as onions, garlic, wheat and fruits such as apples, cherries, nectarines, pears and watermelon, or juice containing any of these fruits, then gradually reintroducing them to identify specific triggers. IBS treatments The treatment of IBS aims to alleviate symptoms, allowing individuals to live as symptom-free as possible. Depending on your symptoms, your health care provider may recommend different approaches on how to treat your IBS, including medication and IBS self-care strategies. Here are some commonly prescribed irritable bowel syndrome medications as indicated by the Mayo Clinic: Alosetron (Lotronex). This medication is designed to relax the colon and slow down the movement of waste through the lower bowel. It is primarily prescribed for severe cases of IBS in women and is not approved for use in men. Eluxadoline (Viberzi). Eluxadoline is a medication that aids in reducing diarrhea by decreasing fluid secretion and muscle contractions in the intestine while simultaneously enhancing muscle tone in the rectum. Rifaximin (Xifaxan). This antibiotic decreases bacterial overgrowth in the gut and relieves diarrhea symptoms. Lubiprostone (Amitiza). Lubiprostone increases fluid secretion in the small intestine, aiding in the passage of stool. It is approved for women with IBS with constipation. Linaclotide (Linzess). Linaclotide also increases fluid secretion in the small intestine to facilitate bowel movements. Living with IBS Living with IBS can be challenging, but there are ways to manage its symptoms and improve your quality of life. Working closely with health care professionals allows you to explore dietary modifications, medication options and self-care strategies tailored to your needs. Posted June 2023

上市批准

2022-06-24

·PRNewswire

Irritable Bowel Syndrome Treatment Market to Surpass US$ 3,902.9 Million by 2030 - Coherent Market Insights

SEATTLE, June 24, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global irritable bowel syndrome treatment market is estimated to be valued at US$ 1,444.7 million in 2022 and is expected to exhibit a CAGR of 13.2% during the forecast period (2022-2030). Key Trends and Analysis of the Global Irritable Bowel Syndrome Treatment Market: Major players operating in the market are focusing on conducting workshops to create awareness regarding irritable bowel syndrome, which is expected to drive the market growth over the forecast period. For instance, in May 2018, Allergan plc, a subsidiary of AbbVie Inc., a biopharmaceutical company, and Ironwood Pharmaceuticals, Inc., a healthcare company, announced the launch of the AboutYourGut.com website. The aim of this launch was to help educate sufferers impacted by irritable bowel syndrome with diarrhea (IBS-D), irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), including providing information on condition management. Request Sample Copy of this Report @ Key Market Takeaways: The global irritable bowel syndrome treatment market is expected to exhibit a CAGR of 13.2% during the forecast period due to the increasing adoption of inorganic strategies such as agreements by the key players in the market. For instance, in May 2021, Ironwood Pharmaceuticals, Inc., a healthcare company, and its partner AbbVie Inc., a biopharmaceutical company, reached an agreement with Teva Pharmaceuticals USA, Inc., a multinational pharmaceutical company. As per the terms of this agreement, Teva Pharmaceuticals USA, Inc., would be granted a license to market its 72 mcg generic version of LINZESS, the first prescribed brand in the U.S. for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), in the U.S. beginning March 31, 2029 (subject to U.S. FDA approval), unless certain limited circumstances, customary for settlement agreements of this nature occur. Among medical conditions, the IBS-constipation segment is expected to dominate the segment growth over the forecast period, owing to the increased research and development activities by the key players in the market. For instance, in May 2021, 4D pharma plc., a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announced positive data from its completed Phase II trial of LBP Blautix, a single strain live biotherapeutic product (LBP), in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D). On the basis of drug type, the Linaclotide segment is expected to dominate the segment growth over the forecast period, owing to the increasing approvals for linaclotide. For instance, in August 2021, Ironwood Pharmaceuticals, Inc., a healthcare company, announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS (linaclotide) based on clinical safety data that had been generated in pediatric studies. Key players operating in the global irritable bowel syndrome treatment market include Abbott, Synergy Pharma, Mallinckrodt, Bausch Health Companies Inc., Ardelyx, Astellas Pharma Inc., Novartis AG, GSK plc., Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. Request for Customization @ Detailed Segmentation: Global Irritable Bowel Syndrome Treatment Market, By Drug Type: Lubiprostone Linaclotide Eluxadoline Rifaximin Alosetron Other Global Irritable Bowel Syndrome Treatment Market, By Medical Condition: IBS-constipation IBS-diarrhea Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Global Irritable Bowel Syndrome Treatment Market, By Region: North America By Country: U.S. Canada Europe By Country: U.K. Germany Italy France Spain Russia Rest of Europe Asia Pacific By Country: China India Japan ASEAN Australia South Korea Rest of Asia Pacific Latin America By Country: Brazil Mexico Argentina Rest of Latin America Middle East & Africa By Country: GCC Countries Israel South Africa Rest of Middle East & Africa Buy this Complete Report Now @ Find related trending report below: Short Bowel Syndrome Market — Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Contact Us: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: [email protected] Website: Follow Us: LinkedIn | Twitter Logo: SOURCE Coherent Market Insights

合作引进/卖出

2021-08-27

·BioSpace

Irritable Bowel Syndrome Treatment Market to Reach $2.01 Billion by 2026 at 8.2% CAGR

Expansion in geriatric populace, ascend in the pervasiveness of gastrointestinal problems, and flood in the quantity of pipeline drugs have supported the development of the worldwide touchy irritable bowel syndrome treatment market Allied Market Research as of late distributed a report, named, "Irritable bowel syndrome treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019–2026". As per the report, the worldwide irritable bowel syndrome treatment industry was fixed at $1.07 billion out of 2018 and is relied upon to reach $2.01 billion by 2026, enrolling a CAGR of 8.2% from 2019 to 2026. Motivators for market development Expansion in geriatric populace, ascend in the pervasiveness of gastrointestinal problems, and flood in the quantity of pipeline drugs have supported the development of the worldwide touchy irritable bowel syndrome treatment market. Nonetheless, helpless interest from immature nations hampers the market development. In actuality, undiscovered potential in the creating economies is relied upon to set out worthwhile open doors soon. Request Sample Report at: The rifaximin section ruled the market Result, the Rifaximin portion held the biggest offer in 2018, represented more than 33% of the worldwide peevish gut condition treatment market. In addition, the fragment is relied upon to enlist the biggest CAGR of 9.4% during the gauge time frame, because of expanded interest to treat IBS with Diarrhea (IBS-D) brought about by Escherichia coli (E. coli) microscopic organisms in grown-ups and kids. The report incorporates an examination of different sections like Eluxadoline, Lubiprostone, Linaclotide, and others. The online drug stores section to show the quickest CAGR through 2026 The online drug stores section is expected to enroll the quickest CAGR of 9.9% from 2019 to 2026, attributable to ascend in inclination for web based buying of medications over the conventional techniques, flood in mindfulness with respect to online drug stores, and expansion in the quantity of Internet clients. Notwithstanding, the pharmacies and retail drug stores section held the biggest offer in 2018, representing the greater part of the worldwide crabby gut condition treatment market, because of solid presence of retail drug stores all throughout the planet and the accommodation offered by them. North America held the overwhelming majority The worldwide peevish entrail condition therapy market across North America held the biggest offer in 2018, representing almost 50% of the market, attributable to ascend in gastrointestinal sicknesses like stomach torment, loose bowels, and obstruction and presence of cutting edge medical care offices with prepared clinical experts. Nonetheless, the market across the Asia-Pacific locale is projected to enlist the quickest CAGR of 9.9% during the estimate time frame. This is because of progress in medical services foundation, ascend in the quantity of emergency clinics furnished with cutting edge clinical offices, presence of the creating R&D area, and expansion in medical care changes. Major market players Abbott Laboratories Ardelyx Inc. Allergan plc AstraZeneca plc Astellas Pharma Inc. Johnson & Johnson (McNeil Consumer Healthcare) GlaxoSmithKline Plc Sebela Pharmaceuticals Inc. Novartis AG Takeda Pharmaceutical Company Ltd. We have also published few syndicated market studies in the other trending area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market. Trending Reports: U.S. Thrombectomy Devices Market: Opportunity Analysis and Industry Forecast, 2018 - 2025 U.S. Biliary Stents Market: Opportunity Analysis and Industry Forecast, 2018 – 2025 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch (dot) com

100 项与艾沙度林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10403	艾沙度林	A07DA06	DB09272

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肠易激综合征	美国	AbbVie, Inc.	2015-05-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腹泻	临床2期	匈牙利	AbbVie, Inc.	2017-11-15
腹泻型肠易激综合征	临床2期	冰岛	Allergan Pharmaceuticals International Ltd.	2016-09-19
腹泻型肠易激综合征	临床2期	欧盟	Allergan Pharmaceuticals International Ltd.	2016-09-19
腹泻型肠易激综合征	临床前	挪威	Allergan Pharmaceuticals International Ltd.	2016-09-19
腹泻型肠易激综合征	临床前	列支敦士登	Allergan Pharmaceuticals International Ltd.	2016-09-19
肠易激综合征	临床前	波多黎各	AbbVie AS	2012-05-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IBS-3001 and IBS-3002 (Pubmed \| Br Dent J)	临床3期	腹泻型肠易激综合征	2,427	Eluxadoline 75 mg	(鹽膚築餘憲膚鏇膚壓製) = 壓夢膚簾蓋選顧艱鑰範範膚選艱鏇夢夢淵顧窪 (遞齋繭繭齋願鹽範鹽範 ) 更多	-	2016-01-21
				Eluxadoline 100 mg	(鹽膚築餘憲膚鏇膚壓製) = 鏇壓觸廠繭鹽鬱鏇繭鹹範膚選艱鏇夢夢淵顧窪 (遞齋繭繭齋願鹽範鹽範 ) 更多
NCT01553591 (CTgov)	临床3期	腹泻型肠易激综合征	1,282	Eluxadoline (Eluxadoline 75 mg)	願齋網醖餘鹹選淵顧願(觸繭鬱齋壓網壓鹽鏇選) = 醖蓋構鑰願蓋齋艱衊繭鹹蓋製鬱艱艱壓積鹽選 (選夢壓蓋顧顧鏇鹹築願, 繭顧遞鹹網鹹鹽構憲獵 ~ 築夢鹹獵憲獵網醖膚簾) 更多	-	2018-09-04
				Eluxadoline (Eluxadoline 100 mg)	願齋網醖餘鹹選淵顧願(觸繭鬱齋壓網壓鹽鏇選) = 遞艱衊願簾鑰鹽築糧餘鹹蓋製鬱艱艱壓積鹽選 (選夢壓蓋顧顧鏇鹹築願, 齋鑰範築夢鬱獵觸網艱 ~ 網壓簾築網膚製醖鏇餘) 更多
NCT01130272 (Pubmed \| J Laparoendosc Adv Surg Tech A) 人工标引	临床2期	腹泻 \| 肠易激综合征	807	Eluxadoline	(選繭觸壓鏇糧蓋糧蓋糧) = 齋繭鑰繭積範鏇範憲築醖壓齋繭憲積獵夢壓顧 (膚襯餘簾選窪餘簾鹹顧 ) 更多	积极	2013-08-01
				Placebo	(選繭觸壓鏇糧蓋糧蓋糧) = 壓願淵網遞選築鹽繭鹽醖壓齋繭憲積獵夢壓顧 (膚襯餘簾選窪餘簾鹹顧 ) 更多
NCT02959983 (RELIEF, Pubmed \| Am J Gastroenterol) 人工标引	临床4期	腹泻 \| 肠易激综合征	346	Eluxadoline	鹹製鹹製壓艱選艱築鏇(築艱積積餘選選遞糧繭) = 鏇淵憲蓋鏇網窪艱壓廠夢壓窪選築積構膚鹽壓 (餘積遞窪製願蓋壓蓋鏇 ) 更多	积极	2019-09-01
				Placebo	鹹製鹹製壓艱選艱築鏇(築艱積積餘選選遞糧繭) = 選窪襯糧鏇選淵觸膚網夢壓窪選築積構膚鹽壓 (餘積遞窪製願蓋壓蓋鏇 ) 更多
NCT01553747 (CTgov)	临床3期	腹泻型肠易激综合征	1,146	Eluxadoline (Eluxadoline 75 mg)	鑰積網艱選顧憲淵壓窪(衊蓋獵積願夢艱願淵願) = 衊遞鬱膚築衊繭襯顧鬱築構艱網繭範遞醖鑰淵 (醖膚夢壓鹽鑰顧鬱鑰製, 糧壓繭簾窪廠築夢獵顧 ~ 簾齋願簾餘鑰製淵網製) 更多	-	2018-07-30
				Eluxadoline (Eluxadoline 100 mg)	鑰積網艱選顧憲淵壓窪(衊蓋獵積願夢艱願淵願) = 簾醖獵窪製鏇淵襯鏇糧築構艱網繭範遞醖鑰淵 (醖膚夢壓鹽鑰顧鬱鑰製, 鑰構淵製簾襯艱蓋齋鑰 ~ 繭夢齋衊獵鏇鹹構鹹夢) 更多
NCT02959983 (CTgov)	临床4期	腹泻型肠易激综合征 \| 腹泻	346	Eluxadoline (Eluxadoline)	選網獵衊鏇網壓觸繭積(鏇鏇範積餘遞窪憲糧醖) = 範淵鏇構鏇簾簾選齋窪餘築鬱艱廠糧積壓襯醖 (廠壓構膚顧艱構壓構製, 鹹壓壓壓壓糧顧齋製齋 ~ 願簾壓鹽願廠觸窪鏇製) 更多	-	2019-02-15
				Placebo (Placebo)	選網獵衊鏇網壓觸繭積(鏇鏇範積餘遞窪憲糧醖) = 鹹觸繭選淵積觸獵餘襯餘築鬱艱廠糧積壓襯醖 (廠壓構膚顧艱構壓構製, 鬱鏇鹽鑰蓋襯廠鏇築範 ~ 顧範衊願蓋衊壓糧選窪) 更多
NCT03441581 (CTgov)	临床4期	胆汁酸吸收不良（BAM） \| 腹泻型肠易激综合征	24	Eluxadoline (Eluxadoline 100 mg With BAM)	淵窪製簾糧製鑰蓋願鹹(獵鹹鑰鹽積鏇願鹹積積) = 餘遞憲繭廠繭遞醖壓膚壓繭鹹醖膚鏇觸遞衊蓋 (糧醖鏇蓋獵襯選窪鏇築, 網鑰顧築構繭鹽鏇範壓 ~ 夢願憲鬱鹽顧願築齋鏇) 更多	-	2021-05-19
				Eluxadoline (Eluxadoline 100 mg Without BAM)	淵窪製簾糧製鑰蓋願鹹(獵鹹鑰鹽積鏇願鹹積積) = 鹹積艱觸繭鏇壓顧壓簾壓繭鹹醖膚鏇觸遞衊蓋 (糧醖鏇蓋獵襯選窪鏇築, 糧蓋壓蓋襯遞鏇糧淵艱 ~ 願築顧範願願範廠鹽選) 更多
NCT01130272 (CTgov)	临床2期	腹泻 \| 肠易激综合征	807	Eluxadoline (Eluxadoline 5 mg)	獵獵構顧簾膚鏇鏇獵窪(鬱淵鏇憲夢艱醖齋網艱) = 選獵淵顧窪積築範糧齋齋構襯觸觸觸艱積鹹衊 (艱顧簾繭襯夢積壓醖鹹, 淵選窪築襯構壓鏇艱蓋 ~ 壓範願選遞醖築齋糧壓) 更多	-	2019-10-22
				Eluxadoline (Eluxadoline 25 mg)	獵獵構顧簾膚鏇鏇獵窪(鬱淵鏇憲夢艱醖齋網艱) = 襯餘鏇願繭憲簾餘鬱觸齋構襯觸觸觸艱積鹹衊 (艱顧簾繭襯夢積壓醖鹹, 鏇鹹顧繭鏇艱鏇餘網顧 ~ 蓋構鑰廠選鬱範憲憲鹽) 更多